See how these people are conquering their health challenges in Florida
South Florida See how these people are conquering their health challenges in Florida
Florida residents are confronting serious health challenges with support from medical teams, community groups and new technology.
Outreach workers from the Miami-Dade County Homeless Trust provide water and cooling supplies to those most affected by the city's record heat, while WeCount! advocates for better protections for outdoor workers.
Survivors of recent hurricanes in Miami face invisible mental health hurdles, as experts from virtual platforms like Nema Health teach people to recognize and treat PTSD through talk therapies such as cognitive processing therapy.
Meanwhile, stroke survivors find renewed hope with Miami's first use of nerve stimulation devices, which help patients regain movement years after their initial injury. Across these tough situations, Miami's residents and organizations work to adapt, recover and support each other.
Arlet Lara, the first patient in South Florida to get an FDA-approved nerve stimulation implant, does an exercise while Neil Batungbakal, rehabilitation therapist, activates the implant with the black trigger during her physical therapy appointment on Monday, Sept. 9, 2024, at Lynn Rehabilitation Center at Jackson Memorial Hospital. The activation works as positive reinforcement to her muscles when she completes the exercise correctly.
NO. 1: A STROKE CHANGED A MIAMI TEACHER'S LIFE. HOW A NEW ELECTRICAL DEVICE IS HELPING HER MOVE
What to know about how it works. | Published November 18, 2024 | Read Full Story by Michelle Marchante
Jean Wilfred, 70, enjoys a bottle of water as the outreach team from the Miami-Dade Homeless Trust handed out bottles of water to individuals living on the street on Aug. 1, 2024, in Miami, Florida, during a period of sweltering heat. By Carl Juste
NO. 2: 'WE NEED WATER.' HOW SOUTH FLORIDA GROUPS ARE HELPING THOSE HARDEST HIT BY EXTREME HEAT
Miami-area nonprofits are helping those most vulnerable to the extreme heat South Florida is facing. | Published October 30, 2024 | Read Full Story by Mimi Whitefield
Juan Jose Muñoz (left) and Elvin Antonio Urbina walk with her belongings through the flooded N 15th St in North Tampa, Thursday, October 10, 2024, a day after Hurricane Milton crossed Florida's Gulf Coast. By Pedro Portal
NO. 3: FLORIDIAN HURRICANE SURVIVORS COULD BE SUFFERING FROM PTSD—BUT RECOVERY IS POSSIBLE
After a tumultuous hurricane season, an expert says Floridians should look out for symptoms of PTSD. | Published November 27, 2024 | Read Full Story by Denise Hruby
The summary above was drafted with the help of AI tools and edited by journalists in our News division. All stories listed were reported, written and edited by McClatchy journalists.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Advocates push for override of governor's veto on repealing ‘free kill' law
Advocates are pushing state lawmakers to override Gov. Ron DeSantis' veto of a bill to repeal the state's so-called 'free kill' law. The bill would have repealed the controversial law that blocks some families from suing if they lose a loved one to medical negligence. One of those protesting the veto was Daryl Perritt, whose son died from a blood clot six months ago. He blames the doctors and hospital, as well as the state. "Because of this law, I can't require, demand or get any answer as to why they waited nearly four days to perform that surgery. Had they performed the surgery in the first 24 hours or 48 hours, he would be here with me today," Perritt. He and others have fought to have it repealed, and they came close when the Legislature voted in favor of getting rid of the 30-year-old law. But DeSantis vetoed it last week, saying it would increase hiring costs for Floridians and make it harder to hire and retain doctors in the state. But that hasn't stopped Perritt's fight. It fueled it. He spent thousands of dollars on billboards calling out DeSantis and lawmakers who don't support a repeal. The hope is that the Legislature will override the veto. It will take a two-thirds vote in the State House and Senate to do so. Lawmakers have said a veto is up for discussion. They think there may be enough votes in the House but not the Senate. Lawmakers are back in Tallahassee, working on the budget. Perritt will be meeting with lawmakers to tell them how important an override will be. 'I don't need money. I need my son. And since I can't have my son, I need answers. That's all. I just need answers to why my son is dead. I don't think that's too much to ask,' he said. Click here to download our free news, weather and smart TV apps. And click here to stream Channel 9 Eyewitness News live.
Business Upturn
an hour ago
- Business Upturn
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only in the U.S. and FDA-approved androgen receptor inhibitor (ARi) for the treatment of patients with hormone-sensitive prostate cancer (mHSPC), in combination with androgen deprivation therapy (ADT), with or without chemotherapy. This third approval is based on positive results from the pivotal Phase III ARANOTE trial and broadens the indication profile of darolutamide in mHSPC, enabling its use in combination with ADT, with or without chemotherapy (docetaxel). Darolutamide plus ADT reinforces the established safety and tolerability profile of darolutamide for prostate cancer patients across all approved indications. Orion's collaboration partner Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with androgen deprivation therapy (ADT) for use in patients with metastatic castration-sensitive prostate cancer (mCSPC), which is also known as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on positive results from the pivotal Phase III ARANOTE trial, which showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mHSPC. With this approval, darolutamide plus ADT is indicated in the U.S. for the treatment of adult patients with mHSPC either with or without docetaxel. In addition, darolutamide is approved for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Prostate cancer is the second most common cancer in men and the fifth most common cause of cancer death in men worldwide.1 In 2022, an estimated 1.5 million men were diagnosed with prostate cancer, and about 397,000 died from the disease worldwide.1 Prostate cancer diagnoses are projected to increase to 2.9 million by 2040.2 Darolutamide, under the brand name Nubeqa®, is already approved in mHSPC in combination with ADT and docetaxel in over 85 markets around the world. It's also approved in combination with ADT for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease in more than 85 countries around the world. An approval process in the EU for the treatment of mHSPC in combination with ADT (without docetaxel) is already underway by Bayer. Nubeqa achieved blockbuster status in September 2024, with annual sales reported by Bayer reaching EUR 1.52 billion for the full year of 2024. Darolutamide is developed jointly by Orion and Bayer. About the ARANOTE trial The ARANOTE trial is a randomized, double-blind, placebo-controlled Phase III study designed to assess the efficacy and safety of darolutamide plus ADT in patients with mHSPC. 669 patients were randomized 2:1 to receive 600 mg of darolutamide twice daily or matching placebo in addition to ADT. The primary endpoint of this study is rPFS, measured as time from randomization to date of first documented radiological progressive disease or death due to any cause, whichever occurs first. Secondary endpoints include overall survival (time to death from any cause), time to first castration resistant event, time to initiation of subsequent anti-cancer therapy, time to prostate-specific antigen (PSA) progression, PSA undetectable rates, time to pain progression, and safety assessments. Results from the Phase III ARANOTE trial presented at ESMO 2024 and published in The Journal of Clinical Oncology showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001), in patients with mHSPC. Consistent benefits in radiological progression-free survival (rPFS) were observed across prespecified subgroups, including patients with high-volume (HR 0.60, 95% CI: 0.44-0.80) and low-volume (HR 0.30, 95% CI: 0.15-0.60) mHSPC. The incidence of adverse events in the treatment group with darolutamide plus ADT in the ARANOTE study was comparable to placebo plus ADT. Darolutamide plus ADT was generally well tolerated and showed lower discontinuation rates due to adverse events compared to placebo plus ADT. About darolutamide Darolutamide is an oral ARi with a unique chemical structure that binds with high affinity to the androgen receptor and exhibits a strong antagonistic effect against the androgen receptor inhibiting the receptor function and the growth of prostate cancer cells. Additionally, preclinical models and neuroimaging data in healthy humans support darolutamide's low potential for blood-brain barrier penetration. Darolutamide (plus ADT or plus ADT and docetaxel) demonstrated a side effect profile in both registrational studies in mHSPC where the incidences of adverse events were roughly similar to the respective comparator arm. Darolutamide is a treatment option for doctors and patients, considering its tolerability and low risk of drug interaction. A robust clinical development program is underway investigating darolutamide across various stages of prostate cancer. The program includes the Phase III ARASTEP trial evaluating darolutamide plus ADT compared to ADT alone in hormone-sensitive high-risk biochemical recurrence (BCR) prostate cancer, who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. Furthermore, darolutamide is also being investigated by Bayer in the collaborative Phase III DASL-HiCaP (ANZUP1801) trial led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). The study evaluates darolutamide as an adjuvant treatment for localized prostate cancer with very high risk of recurrence. About metastatic hormone-sensitive prostate cancer At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. mHSPC is a stage in the disease where the cancer has spread outside of the prostate to other parts of the body. Up to 10% of men will present with mHSPC when first diagnosed.3,4,5 For patients with mHSPC, ADT is the cornerstone of treatment, in combination with chemotherapy docetaxel and/or an androgen receptor inhibitor (ARi). Despite treatment, most men with mHSPC will eventually progress to castration-resistant prostate cancer (CRPC), a condition with limited survival. Contact person: Tuukka Hirvonen, Investor Relations tel. +358 10 426 2721 References Bray F et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Accessed: September 2024. James ND et al. Lancet 2024; 403: 1683–722. Piombino C et al. Cancers (Basel). 2023 Oct 11;15(20):4945. Helgstrand JT et al. Cancer. 2018;124(14):2931-2938. Buzzoni C et al. Eur. Urol. 2015;68:885–890. Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finland Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Fox News
2 hours ago
- Fox News
Cannabis
Cannabis is a drug that comes from the dried leaves, flowers, stems, and seeds of a cannabis sativa plant. Cannabis is commonly referred to as weed or marijuana, though marijuana refers to a specific part of the cannabis plant that contains high amounts of the psychoactive compound THC (tetrahydrocannabinol), which has mind-altering effects. CBD (cannabidiol) is another compound found in cannabis. In a single year, 52.5 million people in the United States use cannabis at least once, according to 2021 data from the Centers for Disease Control and Prevention (CDC). Cannabis has a direct effect on the brain, specifically the parts used for learning, decision-making, emotion, memory, reaction time, coordination, and attention, the CDC states. Marijuana is commonly smoked for recreational purposes. There are few prescription cannabis drugs approved by the Food and Drug Administration (FDA) for medicinal purposes. One example is Epidiolex, which is used to treat seizures. The legalization of marijuana is a varying issue on a state-by-state basis. Some states have legalized marijuana for medicinal purposes, while in others marijuana is legal for both recreational and medicinal purposes. Idaho, Kansas, South Carolina and Wyoming are the only states where marijuana is fully illegal.
